Bayer CEO Bill Anderson’s prescription for the company’s ailing performance is to tackle bureaucracy by removing layers of management. As this operational overhaul gets underway, Bayer continues to review its structure with the spin-off of Consumer Health still on the table.
Addressing investors as the Leverkusen, Germany-based firm reported its Q3 results, Anderson said given Bayer’s poor performance this year, particularly generating
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?